Artelo Biosciences, Inc. (ARTL) · Oct 9, 2026 · Delisting
Nasdaq compliance risk — Company was among ~180 Nasdaq listings below the $5M MVLS threshold
Artelo’s Nasdaq filing says the $5M market-value rule remains stayed, but warns that equity financing and other actions may be needed.
Artelo is a clinical-stage biotech trying to advance ART26.12, its lead FABP5 inhibitor for chemotherapy-induced peripheral neuropathy, alongside ART27.13 for cancer-related anorexia and glaucoma. Its latest public update showed $4.2 million of cash and investments against a $2.4 million quarterly loss, underscoring why access to capital matters while the pipeline remains pre-commercial.
The filing adds a Nasdaq-compliance overhang, not an immediate delisting event. Artelo says Nasdaq’s new rule would require at least $5 million of market value of listed securities and that it was among approximately 180 companies initially below the threshold. 〔0〕 The rule is currently stayed, so there is no new deficiency notice or immediate deadline here.
The practical implication is potential financing pressure if the rule returns. The company explicitly lists its existing at-the-market program, other equity or equity-linked financings, warrant actions, expense control, and continued program advancement as possible compliance tools. 〔1〕 That makes dilution a credible contingency, but not a committed transaction; the filing says Artelo has chosen no particular course of action. 〔2〕
Most of the event was already known, while the filing formalizes the risk. Nasdaq had already announced the rule, the stay, and a proposed change tying the operative date to the stay’s termination. The new information is mainly that Artelo is directly affected and may need to balance listing compliance against funding its clinical programs.
Bottom line: This is a warning about a possible future capital-markets problem, not a present delisting action. It matters because resolving the issue could compete with Artelo’s need to fund clinical development and could involve dilution, but the timing and required response remain unresolved.
Nasdaq rulemaking comments due October 29, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!